Electromed, Inc. (ELMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 15% revenue increase and 38% rise in operating income. The strategic expansion of sales territories and focus on the bronchiectasis market are promising. The $10 million stock repurchase program indicates confidence in the company's value. However, economic uncertainties and unclear management responses about hospital sales create slight concerns. Overall, the sentiment is positive due to strong growth metrics, strategic initiatives, and shareholder returns.
Key Financial Performance
Revenue $16.9 million, representing a 15% year-over-year increase. Growth was broad-based across three primary channels: core home care channel grew 13%, distributor sales increased 41%, and hospital sales surged 52%. Reasons for growth include consistent sales force productivity gains, thoughtful expansion of the sales team, and strategic investments in the hospital channel.
Operating Income $2.7 million, a 38% increase year-over-year, representing 16% of revenue. The increase was driven by operational efficiency and disciplined cost management, which enhanced operating leverage.
Net Income $2.1 million, a 44.9% increase year-over-year, or $0.25 per diluted share compared to $0.16 per diluted share in the prior year. The increase was primarily due to higher revenue and gross profit.
Gross Profit $13.2 million, or 78.1% of net revenues, up from $11.5 million or 78.3% of net revenues. The increase in gross profit dollars was due to increased overall revenue and higher net revenues per device, while the slight decrease in gross profit percentage was attributed to higher costs.
Selling, General and Administrative Expenses $10.3 million, a 9.6% increase year-over-year. The increase was primarily due to higher salaries and incentive compensation related to an increased number of personnel in sales, marketing, and reimbursement teams to process higher patient referrals.
Cash Balance $14.1 million as of September 30, 2025, reflecting a decrease of $1.2 million for Q1 fiscal year 2026. The decrease was primarily driven by share repurchases of $1 million of Electromed common stock.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SmartVest therapy: Recognized as a critical element in treating bronchiectasis, with a focus on airway clearance, infection treatment, and inflammation reduction. The 'Triple Down on Bronchiectasis' campaign has reached over 18,000 individuals, with 3,000 actively engaging.
Smart Order e-prescribe solution: Streamlines prescription workflows, with over 1/3 of orders now submitted electronically, improving efficiency and patient outcomes.
Hospital sales growth: Hospital sales surged 52% year-over-year, driven by strategic investments in this channel.
Home care channel expansion: Core home care channel grew 13% year-over-year, supported by an increase in sales representatives and productivity gains.
CRM system launch: Successfully launched a new CRM system on time and on budget, enhancing field productivity and market insights.
Manufacturing optimization: Completed a restructuring of the manufacturing facility to improve production efficiency without disrupting patient deliveries.
Stock repurchase program: Board authorized a $10 million stock repurchase program, reflecting confidence in the company's value.
Focus on bronchiectasis market: Targeting the large, underserved market of nearly 800,000 diagnosed patients and over 4 million undiagnosed individuals in the U.S.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Risks: Electromed remains vigilant for potential issues with primarily domestic suppliers who may have tariff exposure within their upstream supply chains. This could impact the company's ability to maintain its strong track record of on-time delivery and gross margins.
Market Penetration Challenges: Despite the large addressable market for bronchiectasis treatment, only 16% of diagnosed patients are using high-frequency chest wall oscillation therapy. Additionally, there are over 4 million undiagnosed individuals, highlighting a significant gap in market penetration and education.
Operational Risks: The company recently completed a manufacturing optimization plan and launched a new CRM system. While these initiatives were executed without disruptions, any future operational changes or system upgrades could pose risks to productivity and patient deliveries.
Regulatory and Competitive Pressures: Electromed operates in a highly regulated healthcare environment and faces competitive pressures in the medical device industry, which could impact its ability to sustain growth and profitability.
Economic Uncertainties: The company’s financial performance could be affected by broader economic conditions, which may influence patient spending, hospital budgets, and overall demand for medical devices.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to continue delivering double-digit top-line growth for fiscal year 2026, supported by investments in commercial infrastructure and sales force expansion.
Market Opportunity: Electromed aims to address the large and underserved market for bronchiectasis treatment, with nearly 800,000 diagnosed patients and over 4 million undiagnosed individuals in the U.S. as potential beneficiaries of its SmartVest system.
Operational Efficiency: The company plans to maintain gross margins in the mid-70s or better, leveraging its U.S.-based operations and manufacturing optimization initiatives.
Sales Force Expansion: Electromed has increased its direct home care sales force to 57 representatives and plans to continue expanding to support long-term growth.
Productivity Enhancements: The company has implemented a new CRM system and Smart Order e-prescribe solution to improve sales team productivity and prescription processing efficiency.
Clinical Education and Advocacy: Electromed will continue investing in clinical education and advocacy to promote early diagnosis and appropriate prescribing of SmartVest therapy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: As previously announced in fiscal 2026 Q1, our Board authorized a $10 million stock repurchase program. This reinforces our belief that Electromed remains a compelling investment and continues our commitment to returning value to shareholders.
Share Repurchases: The cash balance reflects a decrease of $1.2 million for Q1 fiscal year 2026. The decrease in cash for the quarter was driven primarily by share repurchases of $1 million of Electromed common stock.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you seeing growth in your profile from improved awareness, new users, or existing prescribers?
A:The growth is attributed to adding sales reps, increased clinical awareness, and market awareness efforts by a new pharmaceutical entrant. The company is gaining market share as a single-product company focused on bronchiectasis.
Q:Do you envision pathways to treat a broader patient population from a reimbursement standpoint?
A:The company agrees that earlier treatment is beneficial and is working on publishing a manuscript to raise awareness. Many patients already meet reimbursement guidelines but are not put on therapy sooner. The reimbursement criteria are unlikely to change, but prescribing physicians may become more open to earlier therapy.
Q:Are there additional opportunities for growth in the neuromuscular segment?
A:Yes, there are opportunities in the neuromuscular segment and other diseases like cystic fibrosis. The company plans to focus on prevalent disease states where reimbursement is possible, aiming to unlock the market opportunity of 800,000 diagnosed patients not on therapy and 4.1 million undiagnosed with bronchiectasis-COPD overlap.
Q:Do you have dedicated reps for the hospital channel?
A:Yes, the company has 3 sales reps focused on the hospital channel. The hospital sales cycle is longer and involves capital sales, but the company is investing deliberately in this space. They also have a contract with Vizient, representing half the health systems in the country.
Q:What is the visibility in the hospital sales pipeline, and is $1 million per quarter a new baseline?
A:The hospital business is less predictable due to operating budgets and decision-making processes. The company expects 20%+ growth in this segment year-over-year but emphasizes its primary focus remains on the home care segment.
Q:How do clinicians' treatment algorithms evolve with the new pharmaceutical option?
A:The new drug has raised awareness for bronchiectasis but does not clear mucus, which is where the company's technology comes in. The drug is expensive ($85,000 per patient per year) and lacks reimbursement from CMS or commercial payers. The company's technology is more cost-effective and complementary to the drug.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the predictability of the hospital sales pipeline and whether $1 million per quarter is a new baseline, citing unpredictability due to operating budgets and decision-making processes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABCs bronchiectasis
America leader
Bronchiectasis Research
CEU professional
Cunniff
Distributor sale
Electromed Instructions
Electromed investment
Electromed leverage
Electromed lie
Electromed product
Greetings Electromed
Hospitals patient
Magazine ranking
NTM Bronchiectasis
Number airway
PL improvement
Registry patient
Relations today
Research Registry
States bronchiectasis
States security
United States
channel
company
delivery
diagnosis
disruption
education
fulfillment
gap
group
home care
individual
intervention
sale force
strength
ELMD Transcript
Electromed, Inc. (ELMD) Q3 2026 Earnings Call Transcript
Positive5-12
Electromed's earnings report shows strong financial performance with a 10% revenue growth and a 20% increase in net income, supported by improved gross margins and operational efficiencies. Despite a slight increase in operating expenses, the company's financial health remains robust with increased cash flow. The absence of negative insights from the Q&A session further supports a positive outlook. These factors suggest a likely positive stock price movement over the next two weeks.
Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript
Positive2-10
The earnings report shows strong financial metrics with revenue, operating income, and EPS all increasing significantly. The company's strategic focus on expanding its sales force and product awareness has paid off, particularly in the homecare segment. The approval of a stock repurchase plan and actual buybacks signal confidence in future prospects. While SG&A expenses have risen, the overall financial health remains robust. The Q&A session highlighted growth opportunities and strategic initiatives. Despite minor concerns about rep productivity, the strong financial performance and strategic initiatives suggest a positive stock price movement.
Electromed, Inc. (ELMD) Q1 2026 Earnings Call Transcript
Positive11-12
The earnings call highlights strong financial performance with a 15% revenue increase and 38% rise in operating income. The strategic expansion of sales territories and focus on the bronchiectasis market are promising. The $10 million stock repurchase program indicates confidence in the company's value. However, economic uncertainties and unclear management responses about hospital sales create slight concerns. Overall, the sentiment is positive due to strong growth metrics, strategic initiatives, and shareholder returns.
Electromed, Inc. (ELMD) Q4 2025 Earnings Call Transcript
Positive8-26
The earnings call highlights strong financial performance, with significant revenue and net income growth, improved gross margins, and efficient cash management. Positive developments include successful sales team expansion, effective CRM implementation, and promising hospital channel growth. The Q&A section reveals favorable analyst sentiment and market expansion opportunities, despite some management vagueness. The company's proactive strategies, including share repurchases and manufacturing optimization, support a positive outlook. Overall, the combination of strong earnings, optimistic guidance, and strategic initiatives suggests a positive stock price movement over the next two weeks.
ELMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
